Business Context and Reporting Period
Anika Therapeutics, Inc. filed its Quarterly Report on Form 10-Q for the period ended September 30, 2007. The company develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for tissue protection, healing, repair, and aesthetic enhancement. Key products include ORTHOVISC (osteoarthritis), AMVISC/STAARVISC (ophthalmic), HYVISC (equine), and ELEVESS (aesthetic dermatology). The company operates as a single reportable segment with all operations located in the United States.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2007 | Nine Months Ended Sep 30, 2007 |
|---|---|---|
| Total Revenue | $7,965,380 | $21,202,988 |
| Net Income | $1,796,230 | $4,361,858 |
| Diluted EPS | $0.16 | $0.38 |
| Operating Cash Flow (9mo) | $6,618,094 | |
| Cash & Equivalents (Sep 30, 2007) | $46,159,638 | |
| Total Assets | $81,229,412 | |
| Total Liabilities | $28,606,491 | |
| Stockholders' Equity | $52,622,921 |
Margins (Nine Months 2007): Product gross profit was 54.4% of product revenue. The effective tax rate was 29.2%.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 28.5% for the quarter and 1.2% for the nine-month period compared to 2006. Product revenue rose 32.6% in the quarter but was flat (0.6%) for the nine months.
- Product Mix Shifts:
- ORTHOVISC: U.S. sales surged 67.1% (quarter) and 88.6% (nine months) due to a new Medicare reimbursement code and expanded sales force. International sales fluctuated significantly due to a temporary halt in shipments to Turkey caused by government reimbursement policy changes.
- Ophthalmic: Sales decreased 1.9% (quarter) and 4.3% (nine months) primarily due to timing of orders from major customer Bausch & Lomb.
- HYVISC: Sales increased 42.3% (quarter) and 29.6% (nine months).
- Expenses: Cost of product revenue increased, reducing gross profit margins slightly for the nine-month period. Selling, general, and administrative (SG&A) expenses increased 25.3% in the quarter due to rent and operating costs for a new facility in Bedford, Massachusetts, though they decreased 2.0% for the nine months due to lower legal and consulting costs compared to 2006.
- Capital Expenditures: Investing cash outflows increased significantly to $9.76 million for the nine months, driven by the purchase of a short-term municipal bond ($3.53 million) and capital expenditures for the new facility ($6.23 million).
Outlook, Risks, and Unusual Items
- Galderma Agreement Termination: On November 5, 2007, the company announced it is negotiating to terminate its license and supply agreements with Galderma Pharma regarding the ELEVESS aesthetic product line due to technical and business disagreements. Anika aims to reacquire worldwide rights and commercialize the product independently or with a new partner.
- New Facility Project: The company is constructing a new 134,000 sq. ft. headquarters and manufacturing facility in Bedford, MA. The total project cost is estimated at $28 million, with approximately $20 million expected to be spent or committed in 2007. Financing will likely involve a mix of cash and long-term debt (up to 60%).
- Product Pipeline: The company received CE Mark approval for Monovisc (single-injection osteoarthritis treatment) in October 2007, with a European launch expected in Q1 2008. Clinical trials for Cingal (another osteoarthritis product) are expected to begin in the U.S. in 2008.
- Risks: Key risks include the uncertainty of the Galderma termination terms, the ability to secure financing for the new facility, FDA licensure for the new facility, and continued reimbursement challenges in international markets like Turkey.
Investor Verification Checklist
- Galderma Termination Terms: Verify the final terms of the agreement termination and the timeline for reacquiring ELEVESS rights.
- New Facility Financing: Confirm the status of debt financing for the $28 million Bedford facility project.
- Turkey Reimbursement Impact: Monitor the long-term impact of Turkish reimbursement policy changes on ORTHOVISC international sales.
- ORTHOVISC U.S. Growth: Validate the sustainability of the U.S. sales growth driven by the new Medicare reimbursement code.
- Capital Expenditure Run Rate: Track actual capital spending against the $20 million commitment for 2007 to assess cash burn.